Replies to post #13040 on BioNitrogen Holdings Corp. (BIONQ)

[LongRun8]

Be careful what you wish for.

Mezzanine financing can be toxic depending on the terms. That could send the share price into a death spiral. Many OTC companies that participate in that type of financing have to do it on the financiers terms, not the company's. If they made a deal with Asher Enterprises, or one of the other common toxic financiers, count BION for dead. Asher would drive the share price down and then ultimately be able to convert the debt into millions upon millions of shares (the lower they can drive the share price, the more free-trading shares they would get to flood the market with).

BION's best bet is to get a traditional type of loan, but it seems to me that they are probably existing by issuing shares. It seems like whenever they have a traditional type of debt note due, they have no cash to pay for it.

[Longgg]

You bring up a great point that has had me puzzled for the last 12-18 months, literally this entire operation has been delayed from a lack of cash to pay for the completion of the EPC report. BION has billions (yes with a B and plural) of state backed bond support and cannot complete a fixed cost EPC report because it needs a few million to pay for it, really? Yes EPC reports are technical and complicated, however, for the companies that reside in that market niche its simply another job. My guess is that BION has worn out all the easy and moderate cash funding options and are trolling, the question is will they score sooner or later. If the later, then the options become more and more less favorable for the company. Personally I don't get why the engineering company doesn't simply charge a premium for delay of payment and bake it into the cost of the EPC report, once that is done we are looking at perhaps 8 weeks to complete the bond sale and they get paid. Puzzling indeed...